Pharma manufacturing news in brief
pharmafile | July 18, 2011 | News story | Manufacturing and Production |Â Â pharma manufacturing newsÂ
Our round-up of news in the pharmaceutical manufacturing sector includes facility updates from NanoSonic, Tianyin Pharma, Orchid and Boehringer Ingelheim, plus production contracts for CMOs JHP Pharma and Angel Bio.
NanoSonic Products has established what it claims is the world’s first Good Manufacturing Practice (GMP) facility to make commercial quantities of food and pharmaceutical grade cyclodextrin complexes in Florida, USA. The plant makes use of a proprietary pulse-drying process and will generate all its electrical energy requirements from solar panels. Cyclodextrins are used to improve delivery of active pharmaceutical ingredients.
US contract manufacturing organisation (CMO) JHP Pharmaceuticals says it has won a new contract to produce a “life-saving drug” at its 171,000 sq.ft. sterile injectable and ophthalmic products manufacturing unit in Rochester, Michigan. The agreement covers product transfer and registration batch production for the undisclosed product.
China’s Tianyin Pharmaceutical says it will start production runs at its new 250-tonne macrolide antibiotic manufacturing plant in Jiangchuan by the end of this month. The testing phase will produce batches of azithromycin, with a view to securing GMP certification by China’s State Food and Drug Administration (SFDA).
India’s Orchid Chemicals and Pharmaceuticals has been issued a closure notice by the Tamil Nadu Pollution Control Boardor for violating GMP rules relating to the disposal of solid waste at its cephalosporin manufacturing facility in Alathur, Chennai. The company said it is negotiating with the TNPCB to try to resolve the issues and bring the plant back into operation.
Boehringer Ingelheim has decided to close a facility making veterinary medicines in Fort Dodge, Iowa, in 2014 after losing contracts to make various Pfizer products, reports local newspaper The Messenger. Around 100 jobs will go at the plant between now and 2014, according to Boehringer Ingelheim Vetmedica, although it hopes to transfer as many workers as possible to other facilities in its manufacturing network.
Angel Biotechnology has won a new contract from ReNeuron for development and manufacturing services related to its stem cell therapy ReN001, which is currently in the phase I PISCES clinical trial in ischaemic stroke. The contract extends through to the middle of 2012, said Angel.
Phil Taylor
Related Content
Pharma manufacturing news in brief
Patheon wins a new contract from Boehringer Ingelheim, Ferring buys a UK plant, plus updates …
Bayer planning joint venture to make drugs in Russia
Germany’s Bayer AG has joined a number of its peers in the pharmaceutical industry with …
Pharma manufacturing news in brief
FDA sets aside $35m for manufacturing research, Anteco, Apicore and Vetter provide facility updates and …
